1h Free Analyst Time
Insys Therapeutics Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.Speak directly to the analyst to clarify any post sales queries you may have.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – The publisher's summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights
Insys Therapeutics Inc (Insys) is a specialty pharmaceutical company, which discovers, develops and commercializes novel drug delivery systems of therapeutic compounds. The company harnesses its proprietary sublingual spray technology to develop pharmaceutical cannabinoids. Its marketed products inlcude Subsys, a sublingual fentanyl spray for breakthrough cancer pain (BTCP) and Syndros (dronabinol oral solution), an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in AIDS patients. The company offers its products to oncologists, pain specialists and supportive care centers for the potential treatment of addiction to opioids, opioid overdose and epilepsy. It has operations in the US and offers its products in international markets. Insys is headquartered in Chandler, Arizona, the US.
Insys Therapeutics Inc Key Recent Developments
Jun 27, 2019: Insys Therapeutics becomes first Opioid Company to Declare Bankruptcy
Jun 10, 2019: INSYS Therapeutics initiates court-supervised process to facilitate asset sales and address legacy liabilities
May 10, 2019: INSYS Therapeutics reports first quarter 2019 results
Apr 15, 2019: INSYS Therapeutics Implements Leadership Changes
Mar 07, 2019: INSYS Therapeutics reports fourth quarter and full year 2018 results
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with the publisher's detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Table of Contents
List of TablesList of Figures
Section 1 - About the Company
Section 2 – Company Analysis
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Section 4 – Company’s Recent Developments
Section 5 – Appendix
List of Tables
List of Figures
Companies Mentioned
A selection of companies mentioned in this report includes:
- West Therapeutic Development LLC
- Teva Pharmaceutical Industries Ltd
- Sentynl Therapeutics Inc
- SELLAS Life Sciences Group Inc
- Sanofi
- Roche Holdings Inc
- Par Pharmaceutical Holdings Inc
- Par Pharmaceutical Companies, Inc.
- Merck & Co Inc
- Mallinckrodt LLC
- Kyowa Kirin Co Ltd
- GW Pharmaceuticals Plc
- GlaxoSmithKline Plc
- BioDelivery Sciences International Inc
- Assertio Therapeutics Inc
- AbbVie Inc